Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Sure
2023-506867-33-01Phase 2Authorised
- Sponsor
- GSK
- Start
- Jan 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 30
01
Overview
Phase 2, open-label, single-arm trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Planned start Jan 2022; status: authorised.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-506867-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506867-33-01.